---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-352126"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2026-08-14T20:00:21+00:00"
generated_at: "2026-08-14T20:03:19.840095+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma Q2 net loss $153M, revenue $7.9M, $50M PIPE

## Summary
- Q2 revenue $7.9M vs $3.0M YoY; net loss $153.1M vs $8.5M, driven by one-time charges.
- R&D expenses $49.0M incl. $20M cash to Ascendant and $20M warrant fair value; G&A $46.6M incl. $23M integration and $19.7M stock comp.
- Cash $17.4M at June 30; completed $50M private placement after quarter-end.
- Submitted IND to FDA for CUE-221 in food allergy; Phase 2 data in chronic spontaneous urticaria expected by end of Q3 2026.
- Appointed Dr. Dominic Borie as CMO/Head of R&D and James M. Ahlers as CFO.

## SEC filing metadata
- accession: 0001193125-26-352126
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2026-08-14T20:00:21+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000119312526352126/0001193125-26-352126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000119312526352126/cue-20260814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-352126
- JSON: https://secwatch.observer/filing/0001193125-26-352126.json
- Plain text: https://secwatch.observer/filing/0001193125-26-352126.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.